Breast Cancer Coverage From Every Angle

AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

A poster presentation at the 2017 American Association for Cancer Research Annual Meeting in Washington, DC, detailed interim results of dual HER2 targeting for second-line treatment of metastatic breast cancer. Patients who had received first-line treatment with chemotherapy, trastuzumab, and pertuzumab were enrolled in a phase Ib/II FB-10 dose-escalation trial exploring standard-dose ado-trastuzumab emtansine plus oral neratinib at doses ranging from 120 mg/d to 240 mg/d.

In the 16 patients who were evaluable for efficacy, the objective response rate was 56%: 3 patients had a complete response lasting 17.1 months, 11.9 months, and 12+ months; 6 patients had a partial response; 3 patients had stable disease; and 4 patients had progressive disease. The most frequently observed grade 3 adverse events were diarrhea, nausea, thrombocytopenia, and hypertension.

Additional patients are being enrolled at the 160-mg/d neratinib dose, and phase II studies are planned.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.